annual cash & cash equivalents:
$484.62M+$206.03M(+73.96%)Summary
- As of today (September 17, 2025), PCRX annual cash & cash equivalents is $484.62 million, with the most recent change of +$206.03 million (+73.96%) on December 31, 2024.
- During the last 3 years, PCRX annual cash & cash equivalents has fallen by -$171.79 million (-26.17%).
- PCRX annual cash & cash equivalents is now -26.17% below its all-time high of $656.41 million, reached on December 31, 2021.
Performance
PCRX Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$445.86M-$47.76M(-9.68%)Summary
- As of today (September 17, 2025), PCRX quarterly cash & cash equivalents is $445.86 million, with the most recent change of -$47.76 million (-9.68%) on June 30, 2025.
- Over the past year, PCRX quarterly cash & cash equivalents has increased by +$41.64 million (+10.30%).
- PCRX quarterly cash & cash equivalents is now -35.74% below its all-time high of $693.86 million, reached on September 30, 2021.
Performance
PCRX quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
PCRX Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +74.0% | +10.3% |
| 3 y3 years | -26.2% | +40.9% |
| 5 y5 years | +66.0% | +36.4% |
PCRX Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -26.2% | +74.0% | -9.7% | +156.3% |
| 5 y | 5-year | -26.2% | +74.0% | -35.7% | +156.3% |
| alltime | all time | -26.2% | +6747.8% | -35.7% | +6200.2% |
PCRX Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $445.86M(-9.7%) |
| Mar 2025 | - | $493.63M(+1.9%) |
| Dec 2024 | $484.62M(+74.0%) | $484.62M(+6.8%) |
| Sep 2024 | - | $453.81M(+12.3%) |
| Jun 2024 | - | $404.23M(+24.0%) |
| Mar 2024 | - | $325.89M(+17.0%) |
| Dec 2023 | $278.58M(-3.5%) | $278.58M(+18.5%) |
| Sep 2023 | - | $235.19M(+6.5%) |
| Jun 2023 | - | $220.77M(+26.9%) |
| Mar 2023 | - | $174.00M(-39.7%) |
| Dec 2022 | $288.65M(-56.0%) | $288.65M(-12.2%) |
| Sep 2022 | - | $328.73M(+3.9%) |
| Jun 2022 | - | $316.39M(-30.0%) |
| Mar 2022 | - | $452.19M(-31.1%) |
| Dec 2021 | $656.41M(+25.8%) | $656.41M(-5.4%) |
| Sep 2021 | - | $693.86M(+7.3%) |
| Jun 2021 | - | $646.60M(+9.6%) |
| Mar 2021 | - | $590.06M(+13.1%) |
| Dec 2020 | $521.66M(+78.7%) | $521.66M(-2.0%) |
| Sep 2020 | - | $532.13M(+62.8%) |
| Jun 2020 | - | $326.79M(+2.6%) |
| Mar 2020 | - | $318.46M(+9.1%) |
| Dec 2019 | $291.95M(-23.9%) | $291.95M(+9.9%) |
| Sep 2019 | - | $265.64M(-9.1%) |
| Jun 2019 | - | $292.24M(-29.1%) |
| Mar 2019 | - | $412.44M(+7.6%) |
| Dec 2018 | $383.45M(+23.2%) | $383.45M(-0.8%) |
| Sep 2018 | - | $386.41M(+4.1%) |
| Jun 2018 | - | $371.32M(+9.3%) |
| Mar 2018 | - | $339.79M(+9.1%) |
| Dec 2017 | $311.35M | $311.35M(+5.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2017 | - | $294.08M(-23.1%) |
| Jun 2017 | - | $382.44M(-0.3%) |
| Mar 2017 | - | $383.70M(+122.3%) |
| Dec 2016 | $172.60M(+8.6%) | $172.60M(+7.1%) |
| Sep 2016 | - | $161.13M(-0.9%) |
| Jun 2016 | - | $162.67M(+8.4%) |
| Mar 2016 | - | $150.02M(-5.6%) |
| Dec 2015 | $158.97M(+0.5%) | $158.97M(+8.6%) |
| Sep 2015 | - | $146.44M(-4.4%) |
| Jun 2015 | - | $153.15M(-1.1%) |
| Mar 2015 | - | $154.89M(-2.1%) |
| Dec 2014 | $158.17M(+114.4%) | $158.17M(+4.4%) |
| Sep 2014 | - | $151.56M(-8.7%) |
| Jun 2014 | - | $166.03M(+157.1%) |
| Mar 2014 | - | $64.57M(-12.5%) |
| Dec 2013 | $73.78M(+73.3%) | $73.78M(-12.0%) |
| Sep 2013 | - | $83.82M(-13.5%) |
| Jun 2013 | - | $96.95M(-12.1%) |
| Mar 2013 | - | $110.25M(+159.0%) |
| Dec 2012 | $42.57M(-45.0%) | $42.57M(-38.1%) |
| Sep 2012 | - | $68.74M(-20.2%) |
| Jun 2012 | - | $86.13M(+57.1%) |
| Mar 2012 | - | $54.83M(-29.2%) |
| Dec 2011 | $77.45M(+196.4%) | $77.45M(+99.9%) |
| Sep 2011 | - | $38.76M(-21.3%) |
| Jun 2011 | - | $49.27M(-17.0%) |
| Mar 2011 | - | $59.33M(+127.0%) |
| Dec 2010 | $26.13M(+269.3%) | $26.13M(+88.7%) |
| Sep 2010 | - | $13.85M(+12.1%) |
| Jun 2010 | - | $12.35M(+74.6%) |
| Dec 2009 | $7.08M(-42.9%) | $7.08M |
| Dec 2008 | $12.39M | - |
FAQ
- What is Pacira BioSciences, Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Pacira BioSciences, Inc.?
- What is Pacira BioSciences, Inc. annual cash & cash equivalents year-on-year change?
- What is Pacira BioSciences, Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Pacira BioSciences, Inc.?
- What is Pacira BioSciences, Inc. quarterly cash & cash equivalents year-on-year change?
What is Pacira BioSciences, Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of PCRX is $484.62M
What is the all time high annual cash & cash equivalents for Pacira BioSciences, Inc.?
Pacira BioSciences, Inc. all-time high annual cash & cash equivalents is $656.41M
What is Pacira BioSciences, Inc. annual cash & cash equivalents year-on-year change?
Over the past year, PCRX annual cash & cash equivalents has changed by +$206.03M (+73.96%)
What is Pacira BioSciences, Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of PCRX is $445.86M
What is the all time high quarterly cash & cash equivalents for Pacira BioSciences, Inc.?
Pacira BioSciences, Inc. all-time high quarterly cash & cash equivalents is $693.86M
What is Pacira BioSciences, Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, PCRX quarterly cash & cash equivalents has changed by +$41.64M (+10.30%)